Compass Therapeutics Inc (NASDAQ: CMPX)’s stock price has dropped by -2.70 in relation to previous closing price of 2.41. Nevertheless, the company has seen a loss of -6.20% in its stock price over the last five trading days. https://www.defenseworld.net reported 2025-06-11 that Squarepoint Ops LLC acquired a new stake in Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 24,072 shares of the company’s stock, valued at approximately $35,000. A number of other large investors have also recently added to or reduced their stakes in the business. Rhumbline Advisers grew its stake in Compass Therapeutics by 3.1% in the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock valued at $187,000 after acquiring an additional 3,822 shares during the last quarter. Invesco Ltd. grew its stake in Compass Therapeutics by 11.3% in the 4th quarter. Invesco Ltd. now owns 39,483 shares of the company’s stock valued at $57,000 after acquiring an additional 4,018 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Compass Therapeutics by 2.6% in the 4th quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock valued at $345,000 after acquiring an additional 6,041 shares during the last quarter. ProShare Advisors LLC grew its stake in Compass Therapeutics by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after acquiring an additional 9,451 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in Compass Therapeutics by 31.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company’s stock valued at $69,000 after acquiring an additional 11,326 shares during the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds. Analyst Upgrades and Downgrades CMPX has been the topic of several analyst reports. Guggenheim decreased their price target on shares of Compass Therapeutics from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Leerink Partners raised shares of Compass Therapeutics from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a research note on Tuesday, April 1st. D. Boral Capital reaffirmed a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research note on Monday, April 28th. Finally, Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 1st. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $13.13. View Our Latest Stock Analysis on CMPX Insiders Place Their Bets In related news, insider Jonathan Anderman acquired 20,000 shares of Compass Therapeutics stock in a transaction that occurred on Monday, April 7th. The stock was acquired at an average price of $1.54 per share, with a total value of $30,800.00. Following the completion of the acquisition, the insider now directly owns 21,000 shares of the company’s stock, valued at $32,340. This trade represents a 2,000.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Carl L. Gordon sold 3,571,428 shares of the business’s stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. 29.80% of the stock is currently owned by corporate insiders. Compass Therapeutics Stock Performance CMPX opened at $2.51 on Wednesday. The company’s 50 day simple moving average is $1.95 and its 200 day simple moving average is $2.17. Compass Therapeutics, Inc. has a 1 year low of $0.77 and a 1 year high of $4.08. The stock has a market capitalization of $347.09 million, a PE ratio of -6.78 and a beta of 1.41. Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). As a group, sell-side analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year. Compass Therapeutics Company Profile (Free Report) Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
Is It Worth Investing in Compass Therapeutics Inc (NASDAQ: CMPX) Right Now?
The 36-month beta value for CMPX is also noteworthy at 1.23. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CMPX is 87.95M, and at present, short sellers hold a 8.45% of that float. The average trading volume of CMPX on June 13, 2025 was 1.44M shares.
CMPX’s Market Performance
CMPX’s stock has seen a -6.20% decrease for the week, with a 17.25% rise in the past month and a -4.67% fall in the past quarter. The volatility ratio for the week is 2.65%, and the volatility levels for the past 30 days are at 2.77% for Compass Therapeutics Inc The simple moving average for the last 20 days is 5.22% for CMPX’s stock, with a simple moving average of 15.28% for the last 200 days.
Analysts’ Opinion of CMPX
Many brokerage firms have already submitted their reports for CMPX stocks, with Leerink Partners repeating the rating for CMPX by listing it as a “Outperform.” The predicted price for CMPX in the upcoming period, according to Leerink Partners is $6 based on the research report published on April 02, 2025 of the current year 2025.
Guggenheim, on the other hand, stated in their research note that they expect to see CMPX reach a price target of $12. The rating they have provided for CMPX stocks is “Buy” according to the report published on February 24th, 2025.
Piper Sandler gave a rating of “Overweight” to CMPX, setting the target price at $12 in the report published on February 19th of the current year.
CMPX Trading at 18.55% from the 50-Day Moving Average
After a stumble in the market that brought CMPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.52% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CMPX starting from Schuetz Thomas J., who purchase 10,000 shares at the price of $2.11 back on May 27 ’25. After this action, Schuetz Thomas J. now owns 6,480,825 shares of Compass Therapeutics Inc, valued at $21,100 using the latest closing price.
GORDON CARL L, the Director of Compass Therapeutics Inc, sale 3,571,428 shares at $1.59 during a trade that took place back on Apr 09 ’25, which means that GORDON CARL L is holding 0 shares at $5,678,571 based on the most recent closing price.
Stock Fundamentals for CMPX
Current profitability levels for the company are sitting at:
- -15.01 for the present operating margin
- 0.75 for the gross margin
The net margin for Compass Therapeutics Inc stands at -12.93. The total capital return value is set at -0.38. Equity return is now at value -41.31, with -37.74 for asset returns.
Based on Compass Therapeutics Inc (CMPX), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -6.99. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -29.59.
Currently, EBITDA for the company is -48.47 million with net debt to EBITDA at 0.56. When we switch over and look at the enterprise to sales, we see a ratio of 78.89. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.33.
Conclusion
In summary, Compass Therapeutics Inc (CMPX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
